Athersys, Inc. (ATHXQ)
- Previous Close
0.0044 - Open
0.0044 - Bid --
- Ask --
- Day's Range
0.0044 - 0.0045 - 52 Week Range
0.0018 - 0.0425 - Volume
40,500 - Avg. Volume
388,182 - Market Cap (intraday)
271,563 - Beta (5Y Monthly) -1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Apr 29, 2024 - May 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.
www.athersys.comRecent News: ATHXQ
Compare To: ATHXQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATHXQ
Valuation Measures
Market Cap
271.56k
Enterprise Value
17.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.09
Price/Book (mrq)
--
Enterprise Value/Revenue
222.86
Enterprise Value/EBITDA
-0.44
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.57%
Return on Equity (ttm)
--
Revenue (ttm)
80k
Net Income Avi to Common (ttm)
-37.51M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.45M
Research Analysis: ATHXQ
Company Insights: ATHXQ
ATHXQ does not have Company Insights